AstraZeneca sells its stake holding in Moderna for over US$1 billion
Category: #healthcare  By Mateen Dalal  Date: 2021-03-02
  • share
  • Twitter
  • Facebook
  • LinkedIn

AstraZeneca sells its stake holding in Moderna for over US$1 billion
  • Moderna has projected an expected sales of $18.4 billion from its coronavirus vaccine in 2021
  • The company’s COVID-19 vaccine has gained approval in the U.S., exclusively for emergency use

Following a substantial surge in its shares on the back of its COVID-19 vaccine breakthrough, biopharmaceutical major AstraZeneca Plc has reportedly sold its 7.7% stake in Moderna Inc. for a sum of over $1 billion.

Sources close to the move state that AstraZeneca will be retaining its partnership with Moderna on other disease therapy and could potentially sell its COVID-19 vaccine developed in collaboration with the Oxford University on a commercial basis in future if the virus becomes an endemic.

Meanwhile, Moderna, whose vaccine gained approval in the U.S. exclusively for emergency use, announced an expected sales of $18.4 billion from its COVID-19 vaccine in 2021. The company’s shares surged to over five times last year after it began working on a new mRNA technology-based COVID-19 vaccine.

The vaccine jabs use synthetic genes to signal a message to the immune system to boost immunity that can be produced at a rapid scale compared to conventional vaccines like the one developed by AstraZeneca.

Reports state that AstraZeneca had started investing in Moderna in 2013, financing $240 million upfront, and building up its stake to 7.65% by the end of 2019. Based on Moderna's closing stock price of $104.47 in the year 2020, these estimates could be worth about $3.2 billion.

Incidentally, AstraZeneca's vaccine being developed with Oxford University has not been authorized in the U.S. and utilizes a lowered down version of a chimpanzee common cold virus to provide immunity-building proteins to the body.

In December 2020, U.S. drug manufacturer Merck & Co announced the selling its equity investment in Moderna, however, failed to disclose any details of the sale proceeds.

Source Credit: https://www.businesstoday.in/current/corporate/astrazeneca-sells-77-stake-in-moderna-for-over-1-billion/story/432605.html

 

About Author

Mateen Dalal    

Mateen Dalal

Despite working as a professional testing engineer, Mateen Dalal always held a liking for content creation. Following his passion, he now pens down articles for itresearchbrief.com and a couple of similar portals. Mateen is a qualified electronics and telecommunicat...

Read More>>

More News By Mateen Dalal

Gennova begins enrollment for Phase 1/2 trials of mRNA COVID vaccine
Gennova begins enrollment for Phase 1/2 trials of mRNA COVID vaccine
By Mateen Dalal

India's first mRNA-based COVID-19 vaccine, HGCO19, formulated by Pune-based biotech firm, Gennov...

Robinhood might have omitted certain trade executions from public feed
Robinhood might have omitted certain trade executions from public feed
By Mateen Dalal

As per credible sources, American retail brokerage services provider Robinhood Financial LLC has fai...

U.S. auto industry asks for government aid amidst chip shortage crisis
U.S. auto industry asks for government aid amidst chip shortage crisis
By Mateen Dalal

Several prominent entities from the U.S. auto industry have reportedly urged the federal government ...